Soheil Ashkani-Esfahani1, Seyed Moayed Alavian1, Mohammad Salehi-Marzijarani1. 1. Soheil Ashkani-Esfahani, Seyed Moayed Alavian, Mohammad Salehi-Marzijarani, Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran 14155-3651, Iran.
Abstract
AIM: To determine hepatitis C virus (HCV) infection prevalence in each country of the Middle-East and the overall prevalence of the region. METHODS: In this systematic review, we gathered all documents related to HCV infection prevalence among hemodialysis patients in 17 middle-east countries from April 2006 to March 2016. We selected only cross-sectional studies that had proper sampling and measurement methods as well as a valid statistical analysis. RESULTS: After screening of 7311 documents, 56 studies were selected reporting the prevalence of HCV infection among hemodialysis patients from 10 countries of the region. Seven countries including United Arab Emirates, Afghanistan, Qatar, Bahrain, Kuwait, Oman, Israel, and Cyprus did not have any relevant document; thus, their latest reports were just mentioned. We performed the meta-analysis and determined the prevalence rates for each country as well as the whole region. The overall HCV infection prevalence among hemodialysis patients in the region was reported to be 25.3%; Egypt and Syria had the highest reported rates while Iran and Lebanon had the lowest. Further investigations are still needed to provide more reliable databases, find main risk factors, and to improve diagnosis and treatment plans, particularly in higher prevalent countries. CONCLUSION: Controlling the prevalence and improving the management methods of HCV infection among hemodialysis patients are of a great concern in the Middle-East region.
AIM: To determine hepatitis C virus (HCV) infection prevalence in each country of the Middle-East and the overall prevalence of the region. METHODS: In this systematic review, we gathered all documents related to HCV infection prevalence among hemodialysis patients in 17 middle-east countries from April 2006 to March 2016. We selected only cross-sectional studies that had proper sampling and measurement methods as well as a valid statistical analysis. RESULTS: After screening of 7311 documents, 56 studies were selected reporting the prevalence of HCV infection among hemodialysis patients from 10 countries of the region. Seven countries including United Arab Emirates, Afghanistan, Qatar, Bahrain, Kuwait, Oman, Israel, and Cyprus did not have any relevant document; thus, their latest reports were just mentioned. We performed the meta-analysis and determined the prevalence rates for each country as well as the whole region. The overall HCV infection prevalence among hemodialysis patients in the region was reported to be 25.3%; Egypt and Syria had the highest reported rates while Iran and Lebanon had the lowest. Further investigations are still needed to provide more reliable databases, find main risk factors, and to improve diagnosis and treatment plans, particularly in higher prevalent countries. CONCLUSION: Controlling the prevalence and improving the management methods of HCV infection among hemodialysis patients are of a great concern in the Middle-East region.
Authors: V Liakina; S Hamid; J Tanaka; S Olafsson; A I Sharara; S M Alavian; L Gheorghe; E S El Hassan; F Abaalkhail; Z Abbas; A Abdou; A Abourached; F Al Braiki; F Al Hosani; K Al Jaberi; M Al Khatry; M A Al Mulla; H Al Quraishi; A Al Rifai; Y Al Serkal; A Alam; H I Alashgar; S Alawadhi; L Al-Dabal; P Aldins; F Z Alfaleh; A S Alghamdi; R Al-Hakeem; A A Aljumah; A Almessabi; A N Alqutub; K A Alswat; I Altraif; M Alzaabi; N Andrea; A M Assiri; M A Babatin; A Baqir; M T Barakat; O M Bergmann; A R Bizri; S Blach; A Chaudhry; M S Choi; T Diab; S Djauzi; S El Khoury; C Estes; S Fakhry; J I Farooqi; H Fridjonsdottir; R A Gani; A Ghafoor Khan; A Goldis; M Gottfredsson; S Gregorcic; B Hajarizadeh; K H Han; I Hasan; A Hashim; G Horvath; B Hunyady; R Husni; W Jafri; A Jeruma; J G Jonasson; B Karlsdottir; D Y Kim; Y S Kim; Z Koutoubi; L A Lesmana; Y S Lim; A Löve; M Maimets; M Makara; R Malekzadeh; M Matičič; M S Memon; S Merat; J E Mokhbat; F H Mourad; D H Muljono; A Nawaz; N Nugrahini; S Priohutomo; H Qureshi; P Rassam; H Razavi; D Razavi-Shearer; K Razavi-Shearer; B Rozentale; M Sadik; K Saeed; A Salamat; R Salupere; F M Sanai; A Sanityoso Sulaiman; R A Sayegh; J D Schmelzer; A Sibley; M Siddiq; A M Siddiqui; G Sigmundsdottir; B Sigurdardottir; D Speiciene; A Sulaiman; M A Sultan; M Taha; H Tarifi; G Tayyab; I Tolmane; M Ud Din; M Umar; J Valantinas; J Videčnik-Zorman; C Yaghi; E Yunihastuti; M A Yusuf; B F Zuberi; J Gunter Journal: J Viral Hepat Date: 2015-12 Impact factor: 3.728
Authors: Rachel B Fissell; Jennifer L Bragg-Gresham; John D Woods; Michel Jadoul; Brenda Gillespie; Sara A Hedderwick; Hugh C Rayner; Roger N Greenwood; Takashi Akiba; Eric W Young Journal: Kidney Int Date: 2004-06 Impact factor: 10.612
Authors: Mohammed Al-Jamal; Ameen Al-Qudah; Khaldoon F Al-Shishi; Ameera Al-Sarayreh; Linda Al-Quraan Journal: Saudi J Kidney Dis Transpl Date: 2009-05